FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression

... | April 13, 2023

Related Keywords

Canada ,United States ,Scot Ebbinghaus ,Twitter ,Merck Co Inc ,Exchange Commission ,Facebook ,Youtube ,Merck Research Laboratories ,Linkedin ,Instagram ,Statement Of Merck Co Inc ,Drug Administration ,Biologics License Application ,Prescription Drug User Fee Act ,Merck Research ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Merck Co ,Nc Stock Exchange ,News ,Information ,Press Release ,Acceptance ,Ased ,N ,Results ,Rom ,The ,Hase , ,Which ,Howed ,Significant ,Verall ,Survival ,Benefit ,These ,Patients ,Ith ,Regardless ,F Mrk Us58933y1055 ,